Phase I Study of Multiple-Vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-Small Cell Lung Cancer
URLC10 and TTK have been identified as cancer specific molecules especially in non small
cell lung cancer using genome-wide expression profile analysis by cDNA microarray technique.
We have determined the HLA-A*2402 restricted epitope peptides derived from these molecules.
We also tend to use the peptides targeting to tumor angiogenesis. VEGF receptor 1 and 2 are
essential targets to tumor angiogenesis, and we identified that peptides derived from these
receptors significantly induce the effective tumor specific CTL response in vitro and vivo.
According to these findings, in this trial, we evaluate the safety, immunological and
clinical response of those peptides.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse effects, dose limiting toxicity, and maximum tolerated dose as measured by CTCAE ver3.0 pre treatment, during study treatment, and 3 months after treatment
Mitsukazu Gotoh, MD,PhD
Fukushima Medical University, First department of Surgery
Japan: Ministry of Health, Labor and Welfare